Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
暂无分享，去创建一个
Sung-Bae Kim | M. Buyse | M. Gnant | H. Iwata | C. Barrios | G. von Minckwitz | Kenichi Inoue | S. Chia | F. Holmes | E. Gokmen | B. Moy | S. Delaloge | J. Mansi | Miguel Martín | B. Ejlertsen | A. Chan | Feng Xu | E. Jakobsen | A. Armstrong | B. Yao | A. Joy | Z. Tomašević | R. Šeparović | N. Denduluri | J. Heijns | S. Moran | F. Overkamp | M. Ruíz Borrego | R. Bryce | J. Link | A. Wong | A. Auerbach | A. Bashford | A. Cicėnienė | A. Chan